Showing results (141-150 of 731) with videos related to
Sort By:
Pageof 74
Cancer Cell|March 27, 2018
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 AntibodiesFrederick Arce Vargas, Andrew J S Furness, Kevin Litchfield, et al.Current Oncology Reports|February 8, 2011
Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalitiesAxel Bex, James Larkin, Christian BlankExpert Opinion on Investigational Drugs|April 22, 2011
New targeted therapies for renal cell carcinomaRosalie Fisher, Lisa Pickering, James LarkinFuture Oncology (London, England)|June 1, 2012
BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutationKate Young, Anna Minchom, James LarkinJournal of Immunotherapy (Hagerstown, Md. : 1997)|December 16, 2020
Checkpoint Inhibitor-associated Cutaneous Small Vessel Vasculitis: A Review of the LiteratureBernard Ho, James Larkin, Kara HeelanHealth Promotion International|December 10, 2024
Commercial influences on patient and public involvement: a renewed call for research and actionMarita Hennessy, Tom Fahey, James LarkinFuture Oncology (London, England)|October 6, 2010
Sunitinib for metastatic renal cell carcinomaDeborah Mukherji, James Larkin, Lisa PickeringProgress in Tumor Research|September 18, 2015
Immunotherapies in Early and Advanced Renal Cell CancerBenjamin Kasenda, James Larkin, Martin GoreExpert Opinion on Pharmacotherapy|March 31, 2016
Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutationsLavinia Spain, Maximilian Julve, James LarkinCancer Treatment Reviews|February 15, 2016
Management of toxicities of immune checkpoint inhibitorsLavinia Spain, Stefan Diem, James LarkinPageof 74